View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 27, 2016updated 13 Jul 2022 10:13am

Aerpio Therapeutics begins Phase Ia trial of AKB-4924 to treat IBD

US-based clinical-stage biopharmaceutical company Aerpio Therapeutics has begun its Phase Ia clinical trial of AKB-4924 to treat inflammatory bowel disease (IBD).

US-based clinical-stage biopharmaceutical company Aerpio Therapeutics has begun its Phase Ia clinical trial of AKB-4924 to treat inflammatory bowel disease (IBD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

AKB-4924 is a small molecule, orally administered on a once-daily basis and has been developed as a hypoxia inducible factor 1 alpha (HIF-1α) stabilising agent.

HIF-1α is considered important for the regulation of innate immune responses and maintenance of epithelial barrier function, particularly in the gut.

The randomised, double-blind, placebo-controlled Phase Ia trial is planning to enrol up to 48 healthy volunteers.

"Initiating the clinical development programme for AKB-4924 represents a major milestone."

The trial is primarily focused on testing the safety and tolerability of AKB-4924 when administered in a single dose.

It will also assess the pharmacokinetics and pharmacodynamics profile of AKB-4924.

Aerpio chief scientific officer Kevin Peters said: “Initiating the clinical development programme for AKB-4924 represents a major milestone.

“AKB-4924 has the potential to be the first orally administered agent to target both the resolution of inflammation and the restoration of epithelial barrier function, the two major drivers of IBD pathogenesis.”

Aerpio CEO believes that AKB-4924 can lead to a reduced dependence of IBD patients on steroids or biologics, which poses significant side effects.

AKB-4924 has demonstrated its efficacy in reducing disease activity, with decreased levels of inflammation and preservation of mucosal integrity in multiple in vivo preclinical models of IBD.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena